Lexaria Bioscience Corp. has announced the commencement of its 2026 research and development program, a strategic initiative designed to expand pharmaceutical, intellectual property, and business development opportunities through new and improved formulations. The program represents a focused effort to generate practical results that could lead to industry partnerships and proprietary technology development.
The company revealed details of three studies that represent primary areas of focus during at least the first three quarters of 2026. According to CEO Richard Christopher, these studies are specifically concentrated on increasing the likelihood of pharma industry partnerships and the creation of new intellectual property. Some aspects of the research must remain confidential at this time since successful outcomes could lead to expanded patent development.
The human study, designated GLP-1-H26-7, is expected to be a 5-week parallel group study with three different arms. Primary goals include establishing safety and tolerability, as well as pharmacokinetic evaluation, comparing salcaprozate sodium-inclusive DehydraTECH-semaglutide tablet and capsule compositions to commercially available Wegovy semaglutide tablets under fasted conditions. This study will evaluate differences between DehydraTECH capsules traditionally optimized for intestinal absorption and DehydraTECH tablets experimentally optimized for primarily stomach absorption.
Study GLP-1-H26-7 will expand upon findings from Human Pilot Study #1, which delivered promising pharmacokinetic and safety results with an earlier iteration of SNAC-inclusive DehydraTECH-semaglutide capsules. The new study will be more robust, with approximately 30 subjects expected in each tablet comparison arm and 15 subjects in the capsule study arm, improving statistical reliability of the data generated. Lexaria is working with third-party service providers with the intent of beginning recruitment as early as April, with ethics board submissions to follow. A final study report is expected in the fourth quarter of 2026.
Two animal studies are also progressing rapidly. Animal Study GLP-1-A26-1 is expected to be a large, single-dose study with between 8-11 different arms, testing various SNAC-inclusive DehydraTECH-semaglutide formulations and various DehydraTECH-cannabidiol formulations. Brain samples will be taken since DehydraTECH has previously evidenced superior absorption of active ingredients into brain tissue, an area of intense interest given that GLP-1 drug performance increasingly depends upon brain neurochemistry involvement.
Animal Study GLP-1-A26-2 will focus on delivering DehydraTECH-enhanced retatrutide and amycretin, both GLP-1 drugs Lexaria has never studied before. The inclusion of retatrutide marks the first time the company has worked with a triple agonist targeting GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors. Some study arms will compare pharmacokinetic performance of test articles placed endoscopically in the intestine versus being swallowed to target the stomach, comparing formulation functionality in distinct gastrointestinal dosing regions.
Both animal studies are anticipated to begin by the second quarter of 2026 with final reports expected near the end of the third quarter. Each study will be conducted by independent third-party service providers and individually announced with additional details once ready to proceed. Additional research and development work, not yet disclosed, may be completed during 2026.
This research program matters because it addresses critical challenges in oral drug delivery for GLP-1 medications, which have revolutionized weight loss treatment but face absorption and side effect limitations. Improved delivery systems could enhance patient compliance, reduce side effects, and potentially lower costs through more efficient drug utilization. For the pharmaceutical industry, successful outcomes could lead to new partnership opportunities and intellectual property development in a rapidly growing market segment. The focus on brain absorption is particularly significant as research increasingly shows GLP-1 drug effectiveness depends on central nervous system effects.
Lexaria's DehydraTECH technology has demonstrated ability to increase bio-absorption, reduce side-effects, and deliver drugs more effectively across the blood-brain barrier. The company operates a licensed in-house research laboratory and holds an intellectual property portfolio with 60 patents granted and additional patents pending worldwide. For more information, visit https://www.lexariabioscience.com.
